Oak Ridge, TN, June 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting from June 20-22nd, 2024 at the Rosen Shingle Creek Resort in Orlando, Florida. The AAHFN is a specialty organization dedicated to advancing nursing education, clinical practice, and research to improve heart failure patient outcomes. "The AAHFN Annual Meeting i ...

Data Presented at the American College of Cardiology Scientific Sessions; Research Letter Published in the Prestigious American Heart Journal Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients. Data from both studies demonstrated a lack of c ...

The Premier Event for Cardiovascular Industry Leaders and Clinicians Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring'24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024. The CV Transforum conference, hosted by MedAxiom, an American College of Cardiology company, unites cardiovascular thought leaders from acro ...

450-Bed Hospital Purchases BVA-100™ Blood Volume Analyzer to Launch Heart Failure Program Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces the purchase of Daxor's BVA-100™ at a 450- bed teaching hospital in the greater Chicago area. "Hospitals are utilizing our BVA diagnostic to save money by reducing length of stay while improving Hospital Readmissions Reduction Program (HRRP) quality metrics such as 3 ...

Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Conference Call March 25, 2024 4:00 PM ET Company Participants Michael Feldschuh - CEO Robert Michel - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the Daxor Corporation Conference Call for the Corporate Update and Financial Results for the Year 2023. At this time, all participants are in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. [O ...

公司信息 - Daxor Corporation (NASDAQ:DXR)宣布将于2024年3月25日下午4:00举行投资者电话会议[1] - 公司总裁兼首席执行官Michael Feldschuh和首席财务官Robert Michel将主持电话会议，审查财务业绩并提供公司发展更新[2] - Daxor Corporation是全球血容量测量技术领域的领导者，专注于血容量测试创新，开发和推广了BVA-100®（血容量分析仪），该仪器是FDA批准的唯一一种提供安全、准确、客观血容量状态和组成量化的诊断血液测试[3] - 公司正在进行多项关于心力衰竭治疗的试验，并得到了NIH的支持，同时正在与美国国防部合作开发分析仪器，以改善战斗伤员护理[4]

Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2023. Management reported a NAV of $7.08 per share for fiscal 2023 versus $6.75 for the comparable period in 2022. The unaudited operati ...

Oak Ridge, TN, March 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) in three new hospitals through new analyzer purchases, and the utilization of Daxor's ezBVA Lab service. These new acquisitions further fuel BVA sales growth and underscore its clinical relevance. New client and services wins include: BVA analyzer purchase at a 735-bed non-profit, tertiary, research and academi ...

Only Daxor's BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates Oak Ridge, TN, March 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of blood volume analysis (BVA) in optimizing individualized therapy for heart failure patients with impaired renal function. Data were presented on 259 patients from three centers at ...

Daxor's ezBVA Lab Service Plays a Significant Role in Driving Growth and Fostering Widespread Adoption Oak Ridge, TN, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) through new analyzer purchases and the utilization of Daxor's ezBVA Lab service. These Q4 2023 initiatives have all played a significant role in driving the growth and the widespread adoption of BVA providing a ...